Online GLP-1 Sellers Bypass Clinician Consultations

Two-thirds of online sellers offering GLP-1 receptor agonists did not require a consultation with a clinician before issuing a prescription, according to a secret shopper study. The research involved testing 49 websites that market these medications.

Out of the 49 websites evaluated, only 13 mandated a video consultation with a healthcare provider. A further three websites required a phone call. The remaining websites, representing the majority, proceeded with prescription issuance without any form of direct clinician interaction, raising concerns about patient safety and appropriate medication use.

GLP-1 receptor agonists, such as semaglutide and tirzepatide, are potent medications primarily used for managing type 2 diabetes and obesity. Their use requires careful medical supervision due to potential side effects and contraindications. The study's findings suggest a significant gap in the oversight of online sales for these prescription drugs.

The study's methodology involved posing as potential patients seeking these medications online. The researchers then documented the prescription process, noting the requirements for clinician engagement. The results highlight a widespread practice of circumventing standard medical protocols in the burgeoning market for weight-loss and diabetes medications sold online. This practice could lead to patients receiving prescriptions without a proper assessment of their health status, potential risks, or suitability for the medication.